Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Phase II Study for the Evaluation of Neoadjuvant Treatment With Cabozantinib Pior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Sponsor: Fundacion Oncosur
Terminated
The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive final result analysis was conducted, as presented herein.
Other Renal Cell Carcinoma Metastatic trials with similar outcome
A PHASE2 clinical study on Renal Cell Carcinoma Metastatic and Renal Cell Carcinoma Stage III, this trial is terminated or withdrawn. The trial is conducted by Fundacion Oncosur and has accumulated 3 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE2
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundacion Oncosur
For direct contact, visit the study record on ClinicalTrials.gov .